Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana–Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School. As of 2023, Dana–Farber is ranked the #4 cancer hospital in the world. Two Nobel laureates in Physiology or Medicine are among its past and present faculty. Dana–Farber's research discoveries include the development of the highly successful Gleevec to treat chronic myeloid leukemia.
